Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:HKMPFOTCMKTS:JEXYYOTCMKTS:KNCAYOTCMKTS:LEGIF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHKMPFHikma Pharmaceuticals$27.73$26.64$22.56▼$28.92$6.15B0.571,600 shsN/AJEXYYJiangsu Expressway$24.44$24.60$18.29▼$26.40$6.16B0.182,432 shs3 shsKNCAYKonica Minolta$5.90+0.9%$6.10$4.87▼$9.30$1.46B0.8826 shs452 shsLEGIFLEG Immobilien$84.61-3.0%$79.41$70.74▼$104.10$6.27B0.89297 shs164 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHKMPFHikma Pharmaceuticals0.00%0.00%+5.86%+2.05%+13.18%JEXYYJiangsu Expressway0.00%0.00%-0.24%+7.67%+16.10%KNCAYKonica Minolta0.00%-6.62%-5.03%-9.51%+0.96%LEGIFLEG Immobilien-2.98%+1.83%+1.83%+2.52%-3.73%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHKMPFHikma PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AJEXYYJiangsu ExpresswayN/AN/AN/AN/AN/AN/AN/AN/AKNCAYKonica MinoltaN/AN/AN/AN/AN/AN/AN/AN/ALEGIFLEG ImmobilienN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHKMPFHikma Pharmaceuticals 3.50Strong BuyN/AN/AJEXYYJiangsu Expressway 0.00N/AN/AN/AKNCAYKonica Minolta 0.00N/AN/AN/ALEGIFLEG Immobilien 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest KNCAY, LEGIF, JEXYY, and HKMPF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025HKMPFHikma PharmaceuticalsBNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/3/2025LEGIFLEG ImmobilienBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHKMPFHikma Pharmaceuticals$2.88B2.14$3.28 per share8.46$10.03 per share2.76JEXYYJiangsu ExpresswayN/AN/AN/AN/AN/AN/AKNCAYKonica Minolta$8.04B0.18$1.72 per share3.42$14.78 per share0.40LEGIFLEG Immobilien$1.34B4.67$6.71 per share12.61$109.36 per share0.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHKMPFHikma Pharmaceuticals$190MN/A0.00∞N/AN/AN/AN/A8/7/2025 (Estimated)JEXYYJiangsu ExpresswayN/AN/A0.00∞N/AN/AN/AN/AN/AKNCAYKonica Minolta$29.85M-$0.12N/A6.70N/A-0.40%-0.84%-0.34%7/30/2025 (Estimated)LEGIFLEG Immobilien-$1.70B$2.45N/A∞N/A-52.85%5.27%2.02%8/7/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHKMPFHikma Pharmaceuticals$0.963.46%N/AN/AN/AJEXYYJiangsu Expressway$1.164.75%N/AN/AN/AKNCAYKonica Minolta$0.040.68%N/AN/A N/ALEGIFLEG ImmobilienN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHKMPFHikma Pharmaceuticals0.461.660.98JEXYYJiangsu ExpresswayN/AN/AN/AKNCAYKonica Minolta0.471.541.06LEGIFLEG ImmobilienN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHKMPFHikma PharmaceuticalsN/AJEXYYJiangsu ExpresswayN/AKNCAYKonica MinoltaN/ALEGIFLEG ImmobilienN/AInsider OwnershipCompanyInsider OwnershipHKMPFHikma PharmaceuticalsN/AJEXYYJiangsu ExpresswayN/AKNCAYKonica MinoltaN/ALEGIFLEG ImmobilienN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHKMPFHikma Pharmaceuticals9,100221.89 millionN/ANot OptionableJEXYYJiangsu Expressway4,754251.89 millionN/ANot OptionableKNCAYKonica Minolta39,378247.24 millionN/ANot OptionableLEGIFLEG Immobilien2,00374.11 millionN/ANot OptionableKNCAY, LEGIF, JEXYY, and HKMPF HeadlinesRecent News About These CompaniesLEG Immobilien SE (OTCMKTS:LEGIF) Short Interest UpdateJune 1 at 5:07 AM | marketbeat.comLEG Immobilien (OTCMKTS:LEGIF) Trading 21.3% Higher - Should You Buy?June 1 at 12:17 AM | marketbeat.comEQS-PVR: LEG Immobilien SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distributionMay 30, 2025 | markets.businessinsider.comEQS-PVR: LEG Immobilien SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distributionMay 30, 2025 | markets.businessinsider.comCalculating The Intrinsic Value Of LEG Immobilien SE (ETR:LEG)May 14, 2025 | finance.yahoo.comLEG Immobilien stock falls on lukewarm rental growthMay 13, 2025 | investing.comLEG Immobilien Backs Guidance After Profit, Earnings RiseMay 13, 2025 | marketwatch.comEQS-DD: LEG Immobilien SE: Dr. Volker Wiegel, buyApril 7, 2025 | markets.businessinsider.comLEG Immobilien's (ETR:LEG) Promising Earnings May Rest On Soft FoundationsMarch 15, 2025 | finance.yahoo.comWarburg Research Keeps Their Buy Rating on LEG Immobilien (0QC9)March 14, 2025 | markets.businessinsider.comLEG Immobilien (0QC9) Receives a Buy from JefferiesMarch 11, 2025 | markets.businessinsider.comLEG Immobilien Full Year 2024 Earnings: Misses ExpectationsMarch 11, 2025 | finance.yahoo.comFull Year 2024 LEG Immobilien SE Earnings Call TranscriptMarch 11, 2025 | gurufocus.comUBS Sticks to Their Buy Rating for LEG Immobilien (0QC9)February 11, 2025 | markets.businessinsider.comPositive Report for LEG Immobilien (0QC9) from Warburg ResearchFebruary 11, 2025 | markets.businessinsider.comJefferies Remains a Buy on LEG Immobilien (0QC9)February 10, 2025 | markets.businessinsider.comBNP PARIBAS EXANE Downgrades LEG Immobilien SE (LEGIF)January 8, 2025 | msn.comIs Now The Time To Look At Buying LEG Immobilien SE (ETR:LEG)?January 7, 2025 | uk.finance.yahoo.comKepler Capital Sticks to Their Buy Rating for LEG Immobilien (0QC9)December 8, 2024 | markets.businessinsider.comLEG Immobilien: An Interesting Value Play In The European Real Estate SectorNovember 22, 2024 | seekingalpha.comQ3 2024 LEG Immobilien SE Earnings Call TranscriptNovember 12, 2024 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKNCAY, LEGIF, JEXYY, and HKMPF Company DescriptionsHikma Pharmaceuticals OTCMKTS:HKMPF$27.73 0.00 (0.00%) As of 06/2/2025Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.Jiangsu Expressway OTCMKTS:JEXYY$24.44 0.00 (0.00%) As of 06/2/2025Jiangsu Expressway Company Limited engages in investment, construction, operation, and management of toll roads and bridges in the People's Republic of China. The company operates the Jiangsu section of Shanghai-Nanjing Expressway, Ningchang Expressway, Zhenli Expressway, Guangjing Expressway, Xicheng Expressway, Xiyi Expressway, Zhendan Expressway, Yanjiang Expressway, Jiangyin Bridge, Sujiahang Expressway, Changyi Expressway, Yichang Expressway, and Wufengshan Bridge. As of December 31, 2022, it operated 17 road and bridge projects; and owned approximately 910 kilometers of roads and bridges. The company also offers passenger transportation; and ancillary services, including refueling, catering, shopping, automobile maintenance, advertising and accommodation, etc. In addition, it engages in the real estate development; and sale of electricity and petroleum products. The company was incorporated in 1992 and is headquartered in Nanjing, China. Jiangsu Expressway Company Limited is a subsidiary of JiangSu Communications Holding Co., Ltd.Konica Minolta OTCMKTS:KNCAY$5.90 +0.05 (+0.89%) As of 10:31 AM EasternKonica Minolta, Inc. engages in digital workplace, professional print, healthcare, and industrial businesses in Japan, China, other Asian countries, the United States, Europe, and internationally. It develops, manufactures, and sells multi-functional peripherals, digital printing systems, and related consumables, as well as offers IT and printing solutions and services. The company also provides diagnostic imaging systems, such as digital X-ray diagnostic imaging, diagnostic ultrasound systems, and other systems; digitalization, networking, solutions, and services in the medical field; genetic testing and drug discovery support services; and primary care services. In addition, it offers measuring instruments; functional film displays; organic light emitting diode lighting products; industrial inkjet printheads; lenses for industrial and professional use; and imaging IoT and visual solutions. The company was founded in 1873 and is headquartered in Tokyo, Japan.LEG Immobilien OTCMKTS:LEGIF$84.61 -2.60 (-2.98%) As of 06/2/2025 10:40 AM EasternLEG Immobilien SE, together with its subsidiaries, operates as an integrated property company in Germany. The company engages in the performance of services and management of equity investments; property management and location development; performance of services for third parties and housing industry services; and generation of electricity and heat activities. It also provides information technology (IT) services for third parties; and management services for third-party properties. The company's property portfolio consisted of residential units; commercial units; and garages and parking spaces in North Rhine-Westphalia. LEG Immobilien SE was founded in 1970 and is headquartered in Düsseldorf, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Reasons Amazon Could Be the Best Tech Performer in June Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Applied Digital: CoreWeave’s AI Deal Lights a $7 Billion Fuse Qualcomm: A Technical Deep-Dive Confirms the Worst Rocket Lab Expands Into Payloads: Should You Be Paying Attention? Steel Dynamics Shares Climb After Tariff Announcement Palantir Soars on Government Deals as Valuation Debate Lingers Broadcom Earnings Preview: AVGO Stock Near Record Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
